A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of
LY2963016 compared to those of basal insulin. The study will also gather information on the
safety and tolerability of LY2963016 in healthy participants.
Each study period will be approximately 8.5 days (1.5 days for treatment and 7 day washout
period). There are 4 study periods.